Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase III, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Previously Untreated BRAF V600E/K Mutation-Positive Participants with Unresectable or Metastatic Melanoma. STARBOARD
Randomized Phase II/III Study Of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab In Patients With Unresectable State III Or Stage IV Melanoma
A Randomized Phase II Study of ATR Inhibition in Advanced PD-L1-refractory Merkel Cell Carcinoma: The MATRiX Trial
Study Type: Treatment
Phase: II
NCTID: NCT05947500
Principal Investigator:
Nina Mathew
A PHASE III STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA
Study Type: Treatment
Phase: III
NCTID: NCT06246916
Principal Investigator:
Gary Doolittle
A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib NSC-763760 and Trametinib NSC-763093 in BRAFV600E/K Mutant Melanoma
A Phase II Randomized Study of Adjuvant versus NeoAdjuvant Pembrolizumab MK-3475 for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneious Melanoma
Study Type: Treatment
Phase: III
NCTID: NCT03860883
Principal Investigator:
Luke Selby
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma Phase I and II and Other Solid Tumors Phase I Only.
Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion before Tumor-Infiltrating Lymphocyte Therapy with Lifileucel in Metastatic Melanoma
Study Type: Treatment
Phase: II
NCTID: NCT06151847
Principal Investigator:
Muhammad Umair Mushtaq